 |
|
How to select anti-hepatitis B virus agents for drug-resistance patients?
September 25, 2008HBV infection may lead to acute liver disease, chronic active hepatitis, liver cirrhosis, and hepatocellular carcinoma. Over 350 million people worldwide are estimated to be infected chronically by HBV and are therefore at risk of liver failure, cirrhosis, or hepatocellular carcinoma. The principal treatment for chronic hepatitis B (CHB) involves the use of interferon alpha (IFN-a) or nucleoside analogs. In vitro analysis of clinical HBV isolates is currently difficult for lacking of HBV cellular culture model
A research article to be published on 14 June 2008, in the World Journal of Gastroenterology addresses this question. The research team led by Prof. Yin-Ping Lu from Union Hospital of Tongji Medical College reportd a useful strategy to select anti-HBV agents for drug-resistance patients. The full-length HBV genomic DNA from chronic hepatitis B patients were amplified by polymerase chain reaction (PCR). The amplified HBV DNA fragments were inserted into an universal HBV expression vector respectively. The recombinant plasmids containing 1.1 copies of HBV genome were transient transfected into Huh7 cells and antiviral susceptibility of lamivudine and adefovir were analyzed in vitro model system. Furthermore, the antiviral susceptibility of adefovir in vivo were observed subsequently.
Eight clinical HBV isolates form different individual with lamivudine-resistance were cloned into HBV expression vector, and recombinant plasmids were transcient transfected into Huh7 cells. The results indicated that HBV genome of clinical HBV isolates could effectively replicate and be expressed in Huh7 cells. Adefovir but not lamivudine inhibited HBV replication both in vitro and in vivo.
The novel method described in this article enables rapidly selecting of anti-HBV agents in clinic and will be useful in future studies of antiviral therapy for chronic hepatitis B.
World Journal of Gastroenterology
The novel method described in this article enables rapidly selecting of anti-HBV agents in clinic and will be useful in future studies of antiviral therapy for chronic hepatitis B.
World Journal of Gastroenterology
Hepatocellular Carcinoma Current Events and Hepatocellular Carcinoma News RSSBariatric surgery may resolve liver disease
Obesity is a growing epidemic in the U.S. with a significant increase in prevalence from 15 percent to 32.9 percent from 1980 to 2004. Nonalcoholic fatty liver disease (NAFLD) is an emerging problem related to the obesity epidemic, becoming one of the most common causes of liver disease in the nation.
Genetic analysis predicts whether liver cancer likely to recur
Researchers are poised to unlock the genetic secrets stored in hundreds of thousands of cancer biopsy samples locked in long-term storage and previously thought to be useless for modern genetic research.
A new therapeutic option for human hepatocyte cancer
p53-impaired tumors may be particularly suitable to parvovirus H-1-induced therapy. Although the p53 deficiency in tumors may induce resistance to chemotherapeutic agents, this will not affect the tumor cell susceptibility to H-1 PV-induced oncolytic infections.
To protect against liver disease, body puts cells 'under arrest'
A stable form of cell-cycle arrest known to offer potent protection against cancer also limits liver fibrosis, a condition characterized by an excess of fibrous tissue, according to a new report in the August 22nd Cell, a Cell Press publication.
Senescence in liver cells is found by CSHL scientists to help limit acute tissue damage
Although post-reproductive life in humans is often associated with decline and a loss of powers, an analogous state in certain cells -- called senescence -- is proving to be one of ironic potency. Scientists at Cold Spring Harbor Laboratory (CSHL) today reported that a particular class of senescent liver cells orchestrates a sequence of events in living mice that can limit fibrosis, a natural response of the liver to acute damage.
New study shows potential to treat or prevent viral cancers
A new study, presented at the SNM 55th Annual Meeting, shows that radioimmunotherapy (RIT) targeting viral antigens offers a novel option to treat-or even prevent-many viral cancers by targeting cancer cells expressing viral antigens or infected cells before they convert into malignancy.
CSHL scientists trace causal link between a tumor suppressor gene and liver cancer
Scientists at Cold Spring Harbor Laboratory (CSHL) have taken the search for cancer-causing genes an important step forward. In a newly published paper, they confirm that a gene called DLC1 is a tumor suppressor. They have demonstrated in living mice that its deletion, inactivation or loss precipitates events culminating in an aggressive type of liver cancer closely related to common human epithelial cancers of the liver (also known as hepatocellular carcinoma, or HCC).
Synergistic growth inhibitory effect of herbal extracts against HCC and lung cancer cells
Several herbs with diversified pharmacological properties are known to be rich sources of chemical constituents that may have potential for the treatment of several human cancers. Data from the Department of Preclinical Science, Faculty of Medicine, Thammasat University, demonstrates that the growth inhibitory activity of doxorubicin or cisplatin, as single agents, may be modified in combination with emblic myrobalan or belleric myrobalan extracts and may be synergistically enhanced in some cases.
Anti-HBe may play a role in the progression of the disease of hepatitis B
Genotype D is found to be the only detected type in different clinical forms of HBV infections, including cirrhosis, among residents of southwestern Iran. A significant association between the presence of anti-HBe antibody and increasing ALT levels among either HBeAg-negative or HBeAg-positive individuals was also determined.
High circulating D-dimers are associated with presence of ascites
The liver is the production site of most of the proteins which favour and inhibit the process of coagulation and fibrinolysis.
More Hepatocellular Carcinoma Current Events and Hepatocellular Carcinoma News Articles
 | Hepatocellular Carcinoma This essential book is a compendium of papers written by an international team of world-renowned experts, who cover topics in their respective areas of expertise. Presenting the most up-to-date knowledge of hepatocellular carcinoma, it covers all topics -- including those more controversial ones -- in this rapidly advancing field, from epidemiology to prevention, from molecular biology to gross... |
 | Pathology of Hepatocellular Carcinoma by Masamichi Kojiro This book covers the huge advances made in clinical diagnosis enabling earlier detection, while addressing the recent progress made in treatment of hepatocellular carcinoma (HCC) to enable successful therapy. It draws on the expertise of an internationally recognized author famed for his understanding, knowledge and efforts in defining terms and diagnosis in this area. The text reviews the full... |
 | Therapy for Viral Hepatitis and Prevention of Hepatocellular Carcinoma The first single-topic annual conference on hepatology in Japan was held in November 2002 to discuss therapies for viral hepatitis and the prevention of hepatocellular carcinoma (HCC). Bringing together researchers and clinicians from North America, Europe, Japan, and other parts of Asia, the conference included symposia on the hepatitis C replicon system, new antivirals that lower or prevent the... |
| Questions remain about resection: transplantation appropriate for some patients with HCC.(hepatocellular carcinoma ): An article from: Internal Medicine News by Robert Finn This digital document is an article from Internal Medicine News, published by International Medical News Group on April 1, 2004. The length of the article is 614 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.Citation... | |
| Subclinical hepatocellular carcinoma | |
 | Progress in Hepatocellular Carcinoma Treatment The rising incidence of hepatocellular cancer (HCC) is a cause for concern in all parts of the world today. Epidemiologists predict that HCC will become endemic because of the large numbers of carriers of hepatitis viruses that lead to the chronic liver diseases, which, in turn, are predisposing factors for the development of HCC. The eradication of HCC thus becomes an urgent priority. Against... |
| Hepatocellular Carcinoma (An Atlas of Its Pathology) by M. Kojiro Nakashima | |
 | Researching Hepatocellular Carcinoma in Japan: A Message to the World : Tokyo, July 29, 2000 (Supplement Issue: Oncology 2001, 3) Focusing on the situation and research studies in Japan, this volume discusses the characteristics of hepatocellular carcinoma, including hepatitus B and C viruses, various treatment strategies from surgery to transplants and chemotherapy, and future challenges facing Japan and the... |
| Hepatocellular carcinoma in a patient with human immunodeficiency virus and hepatitis B virus coinfection: an emerging problem?(Case Report): An article from: Southern Medical Journal by Chris B. Hyun, Walter J. Coyle This digital document is an article from Southern Medical Journal, published by Southern Medical Association on April 1, 2004. The length of the article is 3697 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.Citation... | |
| Hepatocellular Carcinoma (Wiley Series on Diseases of the Liver) by Kunio Okuda, Robert L. Peters, Robert Lee Peters |
| © 2008 BrightSurf.com |